Department of Intensive Care, Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon, Hong Kong SAR.
Crit Care. 2019 Sep 18;23(1):319. doi: 10.1186/s13054-019-2596-1.
Patients with acute hypoxemic respiratory failure are at risk for life-threatening complications during endotracheal intubation. Preoxygenation might help reduce the risk of hypoxemia and intubation-related complications. This network meta-analysis summarizes the efficacy and safety of preoxygenation methods in adult patients with acute hypoxemic respiratory failure.
We searched PubMed, EMBASE, and the Cochrane Library Central Register of Controlled Trials through April 2019 for randomized controlled trials (RCT) that studied the use of conventional oxygen therapy (COT), high-flow nasal cannula (HFNC), noninvasive ventilation (NIV), and HFNC and NIV as preoxygenation before intubation in patients with acute hypoxemic respiratory failure. Citations' screening, study selection, data extraction, and risk of bias assessment were independently performed by two authors. The primary outcome was the lowest SpO during the intubation procedure.
We included 7 RCTs (959 patients). Patients preoxygenated with NIV had significantly less desaturation than patients treated with COT (mean difference, MD 5.53, 95% CI 2.71, 8.34) and HFNC (MD 3.58, 95% CI 0.59, 6.57). Both NIV (odds ratio, OR 0.43, 95% CI 0.21, 0.87) and HFNC (OR 0.49, 95% CI 0.28, 0.88) resulted in a lower risk of intubation-related complications than COT. There were no significant mortality differences among the use of NIV, HFNC, COT, and HFNC and NIV during preoxygenation.
In adult patients with acute hypoxemic respiratory failure, NIV is a safe and probably the most effective preoxygenation method.
急性低氧性呼吸衰竭患者在进行气管插管时存在危及生命的并发症风险。预氧合可能有助于降低低氧血症和与插管相关的并发症的风险。本网络荟萃分析总结了成人急性低氧性呼吸衰竭患者预氧合方法的疗效和安全性。
我们检索了 PubMed、EMBASE 和 Cochrane 图书馆对照试验中心数据库,以获取截至 2019 年 4 月的关于常规氧疗(COT)、高流量鼻导管(HFNC)、无创通气(NIV)和 HFNC 与 NIV 作为急性低氧性呼吸衰竭患者插管前预氧合的随机对照试验(RCT)。两位作者独立进行了引文筛选、研究选择、数据提取和偏倚风险评估。主要结局是插管过程中最低 SpO2。
我们纳入了 7 项 RCT(959 例患者)。与 COT 治疗组(平均差异,MD 5.53,95%CI 2.71,8.34)和 HFNC 治疗组(MD 3.58,95%CI 0.59,6.57)相比,接受 NIV 预氧合的患者缺氧程度显著降低。与 COT 相比,NIV(比值比,OR 0.43,95%CI 0.21,0.87)和 HFNC(OR 0.49,95%CI 0.28,0.88)均降低了与插管相关的并发症风险。在 NIV、HFNC、COT 和 HFNC 与 NIV 预氧合期间,患者的死亡率没有显著差异。
在急性低氧性呼吸衰竭的成年患者中,NIV 是一种安全且可能是最有效的预氧合方法。